Health CatalystHCAT
About: Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Employees: 1,500
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
18,317% more call options, than puts
Call options by funds: $21M | Put options by funds: $114K
40% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 20
25% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 48
4% more funds holding
Funds holding: 159 [Q3] → 165 (+6) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
3.0% less ownership
Funds ownership: 88.2% [Q3] → 85.2% (-3.0%) [Q4]
13% less capital invested
Capital invested by funds: $434M [Q3] → $376M (-$57.9M) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Stephens & Co. Jeff Garro 58% 1-year accuracy 7 / 12 met price target | 26%upside $5 | Equal-Weight Maintained | 6 Mar 2025 |
RBC Capital Sean Dodge 39% 1-year accuracy 15 / 38 met price target | 51%upside $6 | Sector Perform Maintained | 27 Feb 2025 |
Stifel David Grossman 41% 1-year accuracy 9 / 22 met price target | 26%upside $5 | Hold Maintained | 27 Feb 2025 |
Piper Sandler Jessica Tassan 25% 1-year accuracy 6 / 24 met price target | 102%upside $8 | Overweight Maintained | 11 Feb 2025 |
Wells Fargo Stan Berenshteyn 30% 1-year accuracy 3 / 10 met price target | 152%upside $10 | Overweight Maintained | 21 Jan 2025 |
Financial journalist opinion
Based on 6 articles about HCAT published over the past 30 days









